Whitehawk Therapeutics, Inc. Common Stock WHWK Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.79M-84.7% | $37.57M+31.0% | $37.93M+24.2% | $144.94M— | $227.57M— | ||
| $88.25M+2,427% | $108.13M+482% | $124.67M+289% | $32.26M— | $3.49M— | ||
| $0-100% | $0-100% | $5.9M-74.2% | $12.44M-32.3% | $18.36M+13.8% | ||
| $0-100% | $0-100% | $5.31M-77.8% | $10.78M— | $16.88M— | ||
| $125.55M-46.0% | $149.01M+143% | $165.04M+113% | $178.67M— | $232.61M— | ||
| $2K-92.0% | $3K-100.0% | $4K-99.9% | $9K— | $25K— | ||
| $127.23M-45.6% | $150.83M+114% | $167.02M+94.9% | $180.82M— | $234M— | ||
| $1.75M-52.3% | $917K-57.5% | $1.63M+18.9% | $3.34M— | $3.66M— | ||
| $11.06M-9.9% | $14.52M-15.0% | $9.85M-37.7% | $8.76M— | $12.27M— | ||
| $11.06M-9.9% | $14.52M-18.6% | $9.85M-41.5% | $8.76M— | $12.27M— | ||
| $4K-100.0% | $4K+100% | $4K-100.0% | $4K— | $300M— | ||
| -$375.44M-44.6% | -$353.25M-6.2% | -$330M-5.0% | -$312.25M— | -$259.64M— | ||
| $116.18M-47.6% | $136.31M+160% | $157.17M+128% | $172.07M+118% | $221.73M+145% | ||
| $127.23M-45.6% | $150.83M+114% | $167.02M+94.9% | $180.82M— | $234M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Whitehawk Therapeutics, Inc. Common Stock's total assets?
- Whitehawk Therapeutics, Inc. Common Stock (WHWK) holds $127.2M in total assets, down 45.6% year over year.
- How much cash does Whitehawk Therapeutics, Inc. Common Stock have?
- Whitehawk Therapeutics, Inc. Common Stock holds $34.8M in cash and equivalents.
- Can Whitehawk Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 11.36 — current assets exceed current liabilities.
- Where does Whitehawk Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.